These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 24030968)

  • 1. Dapagliflozin (Forxiga) for type 2 diabetes?
    Drug Ther Bull; 2013 Sep; 51(9):105-8. PubMed ID: 24030968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ▼ Empagliflozin, diabetes and outcomes.
    Drug Ther Bull; 2016 Jul; 54(7):78-81. PubMed ID: 27417322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin: A Review in Type 2 Diabetes.
    Dhillon S
    Drugs; 2019 Jul; 79(10):1135-1146. PubMed ID: 31236801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes.
    Demaris KM; White JR
    Drugs Today (Barc); 2013 May; 49(5):289-301. PubMed ID: 23724409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
    Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
    Diabet Med; 2015 Jul; 32(7):890-8. PubMed ID: 25817050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
    Nauck MA; Del Prato S; Durán-García S; Rohwedder K; Langkilde AM; Sugg J; Parikh SJ
    Diabetes Obes Metab; 2014 Nov; 16(11):1111-20. PubMed ID: 24919526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin.
    Grandy S; Hashemi M; Langkilde AM; Parikh S; Sjöström CD
    Diabetes Obes Metab; 2014 Jul; 16(7):645-50. PubMed ID: 24443876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT2 inhibition with dapagliflozin -- a novel approach for the management of type 2 diabetes.
    Kilov G; Leow S; Thomas M
    Aust Fam Physician; 2013 Oct; 42(10):706-10. PubMed ID: 24130972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.
    Jabbour SA; Whaley JM; Tirmenstein M; Poucher SM; Reilly TP; Boulton DW; Saye J; List JF; Parikh S
    Postgrad Med; 2012 Jul; 124(4):62-73. PubMed ID: 22913895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dapagliflozin (forxiga®) : SGLT 2 cotransporter inhibitor as glucose-lowering agent in type 2 diabetes].
    Scheen AJ
    Rev Med Liege; 2016 Oct; 71(10):463-469. PubMed ID: 28383856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.
    Avogaro A; Giaccari A; Fioretto P; Genovese S; Purrello F; Giorgino F; Del Prato S
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):763-772. PubMed ID: 28431476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy for type 2 diabetes: dapagliflozin plus metformin.
    Tan X; Hu J
    Expert Opin Pharmacother; 2016; 17(1):117-26. PubMed ID: 26567559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empagliflozin for the treatment of Type 2 diabetes.
    Gangadharan Komala M; Mather A
    Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dapagliflozin combination therapy in type 2 diabetes mellitus.
    Yacoub T
    Postgrad Med; 2016 Jan; 128(1):124-36. PubMed ID: 26571022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
    Davidson JA; Kuritzky L
    Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin is associated with improved glycaemic control and weight reduction at 44 months of follow-up in a secondary care diabetes clinic in the UK.
    Shrikrishnapalasuriyar N; Shaikh A; Ruslan AM; Sharaf G; Udiawar M; Price DE; Stephens JW
    Diabetes Metab Syndr; 2020; 14(3):237-239. PubMed ID: 32247210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries.
    Sabale U; Ekman M; Granström O; Bergenheim K; McEwan P
    Prim Care Diabetes; 2015 Feb; 9(1):39-47. PubMed ID: 24840612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dapagliflozin: Beyond glycemic control in the treatment of type 2 diabetes mellitus].
    Sanz-Serra P; Pedro-Botet J; Flores-Le Roux JA; Benaiges D; Chillarón JJ
    Clin Investig Arterioscler; 2015; 27(4):205-11. PubMed ID: 25648671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.